- Palatin reported a Q4 fiscal 2024 quarter with meaningful top-line sparsity following the December 2023 sale of Vyleesi rights to Cosette Pharmaceuticals, resulting in no recorded product sales for the quarter. The quarter posted revenue of 0.35 million and a net loss of 8.25 million, translating to an EPS of -0.56. Operating expenses remained elevated at 8.69 million, contributing to an EBITDA of -8.13 million and an operating loss of -8.34 million. For the full fiscal year 2024, the company benefited from a $7.8 million gain on Vyleesi’s sale, which helped reduce overall annual operating expenses versus the prior year, but Palatin still ended FY2024 with a net loss of 29.7 million as cash burn persisted.